# IGALMI® (dexmedetomidine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dexmedetomidine

> The FDA approved IGALMI® (dexmedetomidine), sponsored by PFIZER INC (PFE), on April 5, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | IGALMI® (dexmedetomidine) |
| Codes | BXCL501 |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications | opioid withdrawal symptoms in adults with opioid use disorder undergoing a methadone taper, opioid withdrawal symptoms in adults with opioid use disorder, Agitation,Psychomotor |
| Modality |  |
| FDA designations | breakthrough, fast track |

## Timeline

### April 5, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-28, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215390 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220405, review_priority STANDARD; sponsor_name BIOXCEL; product IGALMI (DEXMEDETOMIDINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215390%22
- SEC Form 10-Q (accession 0001104659-25-109880): "On April 6, 2022, we announced that the FDA approved IGALMI® (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults." https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011158): "On April 6, 2022, we announced that the FDA approved IGALMI® (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults." https://www.sec.gov/Archives/edgar/data/1720893/000155837025011158/btai-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007269): "On April 6, 2022, we announced that the FDA approved IGALMI® (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults." https://www.sec.gov/Archives/edgar/data/1720893/000155837025007269/btai-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-003985): "On April 6, 2022, we announced that the FDA approved IGALMI® sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults." https://www.sec.gov/Archives/edgar/data/1720893/000155837025003985/btai-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-003985): "On April 6, 2022, we announced that the FDA approved IGALMI® (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults." https://www.sec.gov/Archives/edgar/data/1720893/000155837025003985/btai-20241231x10k.htm

### December 16, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA021038 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20221216, review_priority STANDARD; sponsor_name HOSPIRA; product PRECEDEX (DEXMEDETOMIDINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021038%22

### June 29, 2023: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2024-11-14, last confirmed 2026-08-13.
- SEC Form 10-K (accession 0001104659-26-036214): "On June 29, 2023, we announced positive topline results from TRANQUILITY II, a randomized, double-blind, placebo-controlled, parallel group trial that evaluated the safety and efficacy of BXCL501 for the acute treatment of Alzheimer's-related agitation in adults 65 years and older with mild to moderate dementia in assisted living facilities ("ALFs") and residential care settings who required minimal assistance with activities of daily living." https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/btai-20251231x10k.htm
- SEC Form 10-K (accession 0001558370-25-003985): "On June 29, 2023, we announced positive topline results from TRANQUILITY II, a randomized, double-blind, placebo-controlled, parallel group trial that evaluated the safety and efficacy of BXCL501 for the acute treatment of Alzheimer's-related agitation in adults 65 years and older with mild to moderate dementia in assisted living facilities ("ALFs") and residential care settings who required minimal assistance with activities of daily living." https://www.sec.gov/Archives/edgar/data/1720893/000155837025003985/btai-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015629): "On June 29, 2023, we announced positive topline results from TRANQUILITY II, a randomized, double-blind, placebo-controlled, parallel group trial that evaluated the safety and efficacy of BXCL501 for the acute treatment of Alzheimer's-related agitation in adults 65 years and older with mild to moderate dementia in assisted living facilities ("ALFs") and residential care settings who required minimal assistance with activities of daily living." https://www.sec.gov/Archives/edgar/data/1720893/000155837024015629/btai-20240930x10q.htm
- SEC Form 10-K (accession 0001558370-25-003985): "On June 29, 2023, we announced positive topline data from our TRANQUILITY II trial, as well as information regarding certain investigator misconduct and noncompliance at a clinical trial site." https://www.sec.gov/Archives/edgar/data/1720893/000155837025003985/btai-20241231x10k.htm
- SEC Form 10-Q (accession 0001104659-26-095965): "On June 29, 2023, we announced positive topline results from our TRANQUILITY II Phase 3 trial." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "On June 29, 2023, we announced positive topline results from our TRANQUILITY II Phase 3 trial." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-25-109880): "On June 29, 2023, we announced positive topline results from our TRANQUILITY II Phase 3 trial." https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011158): "On June 29, 2023, we announced positive topline results from our TRANQUILITY II Phase 3 trial." https://www.sec.gov/Archives/edgar/data/1720893/000155837025011158/btai-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007269): "On June 29, 2023, we announced positive topline results from our TRANQUILITY II Phase 3 trial." https://www.sec.gov/Archives/edgar/data/1720893/000155837025007269/btai-20250331x10q.htm

### June 25, 2024: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2024-11-14, last confirmed 2026-08-13.
- SEC Form 10-Q (accession 0001104659-26-095965): "On June 25, 2024, we announced positive topline results from our post-marketing requirement study evaluating whether tolerance, tachyphylaxis, or withdrawal occur following repeat dosing of the 180 mcg (highest approved dose) of IGALMI®." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "On June 25, 2024, we announced positive topline results from our post-marketing requirement study evaluating whether tolerance, tachyphylaxis, or withdrawal occur following repeat dosing of the 180 mcg (highest approved dose) of IGALMI®." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-036214): "On June 25, 2024, we announced positive topline results from our post-marketing requirement study evaluating whether tolerance, tachyphylaxis, or withdrawal occur following repeat dosing of the 180 mcg (highest approved dose) of IGALMI®." https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/btai-20251231x10k.htm
- SEC Form 10-K (accession 0001558370-25-003985): "On June 25, 2024, we announced positive topline results from our post-marketing requirement study evaluating whether tolerance, tachyphylaxis, or withdrawal occur following repeat dosing of the 180 mcg (highest approved dose) of IGALMI®." https://www.sec.gov/Archives/edgar/data/1720893/000155837025003985/btai-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015629): "On June 25, 2024, we announced positive topline results from our post-marketing requirement study evaluating whether tolerance, tachyphylaxis, or withdrawal occur following repeat dosing of the 180mg (highest approved dose) of IGALMITM." https://www.sec.gov/Archives/edgar/data/1720893/000155837024015629/btai-20240930x10q.htm

### Sep 2024: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-03-03, last confirmed 2025-03-03.
- SEC Form 8-K (accession 0001104659-25-019531): "In September 2024, the Company initiated patient enrollment in its SERENITY At-Home pivotal Phase 3 trial, evaluating the safety of BXCL501, the Company's investigational, proprietary, orally dissolving film formulation of dexmedetomidine, in the at-home setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia." https://www.sec.gov/Archives/edgar/data/1720893/000110465925019531/tm258055d1_8k.htm

### August 15, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Agitation,Psychomotor; Bipolar I Disorder; Bipolar II Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05658510 (Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-15 (ACTUAL); Lead Sponsor BioXcel Therapeutics Inc." https://clinicaltrials.gov/study/NCT05658510

### August 20, 2025: NDA/BLA submission

- Status: scheduled. Date confidence: exact.
- First seen 2025-03-27, last confirmed 2025-07-21.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-047013): "Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting" https://www.sec.gov/Archives/edgar/data/1720893/000110465925047013/tm2514754d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-028776): "Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting" https://www.sec.gov/Archives/edgar/data/1720893/000110465925028776/tm2510663d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-069149): "The primary purpose of the pre-sNDA meeting, scheduled for August 20, 2025, is to gain alignment with the FDA regarding the content and format of the planned sNDA submission, which the Company is preparing." https://www.sec.gov/Archives/edgar/data/1720893/000110465925069149/tm2521267d1_8k.htm

### September 10, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-03-03, last confirmed 2026-08-13.
- SEC Form 10-Q (accession 0001104659-26-095965): "On September 10, 2025, we further announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated BXCL501 had sustained effects on agitation and consistent benefit with repeat dosing." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095965): "On September 10, 2025, we announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects and consistent benefit with repeat dosing." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "On September 10, 2025, we further announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated BXCL501 had sustained effects on agitation and consistent benefit with repeat dosing." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "On September 10, 2025, we announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects and consistent benefit with repeat dosing." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-036214): "On September 10, 2025 we further announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated BXCL501 had continued effects and consistent benefit with repeat dosing." https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/btai-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-036214): "On September 10, 2025, we announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated BXCL501 had continued effects and consistent benefit with repeat dosing." https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/btai-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-109880): "On September 10, 2025 we further announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated BXCL501 had continued effects and consistent benefit with repeat dosing." https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm
- SEC Form 10-Q (accession 0001104659-25-109880): "On September 10, 2025, we announced positive topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated BXCL501 had continued effects and consistent benefit with repeat dosing." https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-047013): "Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting" https://www.sec.gov/Archives/edgar/data/1720893/000110465925047013/tm2514754d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-028776): "Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting" https://www.sec.gov/Archives/edgar/data/1720893/000110465925028776/tm2510663d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-026388): "Topline data results, which are expected in the second half of 2025, are intended to support a supplemental new drug application (sNDA) submission to potentially expand the label of IGALMI® (dexmedetomidine) sublingual film." https://www.sec.gov/Archives/edgar/data/1720893/000110465925026388/tm259958d2_8k.htm
- SEC Form 8-K (accession 0001104659-25-019531): "Topline data results, which are expected in the second half of 2025, are intended to support a supplemental new drug application (sNDA) submission to potentially expand the label of IGALMI® (dexmedetomidine) sublingual film." https://www.sec.gov/Archives/edgar/data/1720893/000110465925019531/tm258055d1_8k.htm

### November 19, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215390 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority STANDARD; sponsor_name BIOXCEL; product IGALMI (DEXMEDETOMIDINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215390%22

### Q1 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-08-18, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-109732): "Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease sNDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based on positive data from the SERENITY-At Home trial" https://www.sec.gov/Archives/edgar/data/1720893/000110465925109732/tm2530979d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-083402): "The data from this successful study will form the basis of the sNDA submission for label expansion of IGALMI® in the at-home setting planned for the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1720893/000110465925083402/tm2524474d1_8k.htm
- SEC Form 10-Q (accession 0001104659-25-109880): "Similarly, we intend to submit an sNDA for label expansion of IGALMI® for the acute treatment of agitation associated with schizophrenia and bipolar disorders in the at-home setting early in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm
- SEC Form 8-K (accession 0001104659-25-079459): "Based on the FDA's feedback, the Company believes that the planned sNDA regulatory package will be sufficient to support the sNDA submission, which remains on track for the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1720893/000110465925079459/tm2523368d4_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-109732): "As part of this update, the Company said it plans to submit early in the first quarter of 2026 a supplemental New Drug Application (sNDA)" https://www.sec.gov/Archives/edgar/data/1720893/000110465925109732/tm2530979d1_ex99-1.htm

### January 20, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2026-03-11, last confirmed 2026-08-13.
- SEC Form 10-Q (accession 0001104659-26-095965): "On January 14, 2026, we submitted a supplemental New Drug Application (sNDA) to the FDA for IGALMI® for the acute treatment of agitation associated with schizophrenia and bipolar disorders in the at-home setting." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095965): "On January 14, 2026 we submitted a sNDA for label expansion of IGALMI® in the at-home setting based on the data from the successful SERENITY At-Home trial, we cannot be certain that our submission will be approved, or that our other product candidates currently in development, or any than may be developed in the future, will be successful in clinical trials or receive regulatory approval." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "On January 20, 2026, we announced we submitted a supplemental New Drug Application, or sNDA, to the FDA for IGALMI® in the at-home use setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "On January 14, 2026, we submitted a supplemental New Drug Application (sNDA) to the FDA for IGALMI® for the acute treatment of agitation associated with schizophrenia and bipolar disorders in the at-home setting." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "On January 14, 2026 we submitted a sNDA for label expansion of IGALMI® in the at-home setting based on the data from the successful SERENITY At-Home trial, we cannot be certain that our submission will be approved, or that our other product candidates currently in development, or any than may be developed in the future, will be successful in clinical trials or receive regulatory approval." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-036214): "On January 14, 2026, we submitted a supplemental New Drug Application (sNDA) to the FDA for IGALMI® for the acute treatment of agitation associated with schizophrenia and bipolar disorders in the at-home setting." https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/btai-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-036214): "On January 14, 2026 we submitted a sNDA for label expansion of IGALMI® in the at-home setting based on the data from the successful SERENITY At-Home trial, we cannot be certain that our submission will be approved, or that our other product candidates currently in development, or any than may be developed in the future, will be successful in clinical trials or receive regulatory approval." https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/btai-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-036214): "On January 20, 2026, we announced we submitted a supplemental New Drug Application, or sNDA, to the FDA for IGALMI® in the at-home use setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia." https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/btai-20251231x10k.htm
- SEC prospectus (424B) (accession 0001104659-26-026158): "On January 20, 2026, we announced that on January 14, 2026 we submitted a supplemental New Drug Application, or sNDA, to the FDA for IGALMI® in the at-home use setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia." https://www.sec.gov/Archives/edgar/data/1720893/000110465926026158/tm2526950-2_424b5.htm
- SEC Form 10-Q (accession 0001104659-26-095965): "We have completed the SERENITY At-Home trial evaluating the safety of BXCL501 and, on January 14, 2026, submitted an sNDA for label expansion of IGALMI® in the at-home setting based on the data from the successful SERENITY At-Home trial and are planning for certain clinical trials relating to BXCL501, BXCL701, BXCL502 and our other product candidates, there can be no assurance that the FDA, or other comparable foreign regulatory authorities, will accept our submission or proposed trial designs as sufficient to establish the safety and/or efficacy of our product candidates." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "We have completed the SERENITY At-Home trial evaluating the safety of BXCL501 and, on January 14, 2026, submitted an sNDA for label expansion of IGALMI® in the at-home setting based on the data from the successful SERENITY At-Home trial and are planning for certain clinical trials relating to BXCL501, BXCL701, BXCL502 and our other product candidates, there can be no assurance that the FDA, or other comparable foreign regulatory authorities, will accept our submission or proposed trial designs as sufficient to establish the safety and/or efficacy of our product candidates." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-036214): "We have completed the SERENITY At-Home trial evaluating the safety of BXCL501 and, on January 14, 2026, submitted an sNDA for label expansion of IGALMI® in the at-home setting based on the data from the successful SERENITY At-Home trial and are planning for certain clinical trials relating to BXCL501, BXCL701, BXCL502 and our other product candidates, there can be no assurance that the FDA, or other comparable foreign regulatory authorities, will accept our submission or proposed trial designs as sufficient to establish the safety and/or efficacy of our product candidates." https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/btai-20251231x10k.htm

### March 5, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2. Indication: opioid withdrawal symptoms in adults with opioid use disorder undergoing a methadone taper.
- First seen 2026-03-27, last confirmed 2026-08-13.
- SEC Form 10-Q (accession 0001104659-26-095965): "On March 5, 2026, the Company announced positive topline results from the Columbia Phase 2 investigator-sponsored trial evaluating BXCL501 for the treatment of opioid withdrawal symptoms in adults with opioid use disorder undergoing a methadone taper." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "On March 5, 2026 we announced positive topline results from a Phase 2 investigator-sponsored trial (IST) evaluating BXCL501 for the treatment of opioid withdrawal symptoms in adults with opioid use disorder (OUD) undergoing a methadone taper." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "On March 5, 2026, the Company announced positive topline results from the Columbia Phase 2 investigator-sponsored trial evaluating BXCL501 for the treatment of opioid withdrawal symptoms in adults with opioid use disorder undergoing a methadone taper." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-036214): "On March 5, 2026, the Company announced positive topline results from the Columbia Phase 2 investigator-sponsored trial evaluating BXCL501 for the treatment of opioid withdrawal symptoms in adults with opioid use disorder undergoing a methadone taper." https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/btai-20251231x10k.htm

### March 27, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-03-27, last confirmed 2026-03-27.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-035661): "Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential approval as early as year-end 2026" https://www.sec.gov/Archives/edgar/data/1720893/000110465926035661/tm269970d1_ex99-1.htm

### April 1, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-04-01, last confirmed 2026-08-13.
- SEC Form 10-Q (accession 0001104659-26-095965): "On April 1, 2026, we announced that the FDA has accepted our sNDA for approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095965): "On April 1, 2026 we announced that the U.S. FDA has accepted the supplemental New Drug Application (sNDA) for approval of IGALMI® for at-home use in the acute treatment of agitation in the home setting." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "On April 1, 2026, we announced that the FDA has accepted our sNDA for approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "On April 1, 2026 we announced that the U.S. FDA has accepted the supplemental New Drug Application (sNDA) for approval of IGALMI® for at-home use in the acute treatment of agitation in the home setting." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 8-K (accession 0001104659-26-038174): ""Company") announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI." https://www.sec.gov/Archives/edgar/data/1720893/000110465926038174/tm2610820d1_8k.htm

### November 14, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-04-01, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-061773): "FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date" https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-061773): "March 31, the FDA accepted the Company's supplemental New Drug Application (sNDA) for IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia and assigned a PDUFA target action date of November 14, 2026." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-26-038174): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026." https://www.sec.gov/Archives/edgar/data/1720893/000110465926038174/tm2610820d1_8k.htm
- SEC Form 10-Q (accession 0001104659-26-095965): "The FDA has assigned a Prescription Drug User Fee Act ("PDUFA") target action date of November 14, 2026." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095965): "Any delays in the FDA's review, feedback or approval of our proposed package design could have a negative impact on the likelihood of receiving approval for our sNDA on the PDUFA target action date of November 14, 2026." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095965): "The OAI is not specifically related to the active pharmaceutical ingredient used in the production of Dex, but nonetheless the OAI could result in a delay or rejection by the FDA in connection with our Prescription Drug User Fee Act ("PDUFA") target action date of November 14, 2026." https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026" https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-061769): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026." https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm

Calendar months: [August 2025](https://sec-api.dev/fda-calendar/2025-08), [November 2026](https://sec-api.dev/fda-calendar/2026-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dexmedetomidine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IGALMI® (dexmedetomidine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dexmedetomidine

```bibtex
@misc{secapidev_pdufa_dexmedetomidine_20261116,
  title        = {IGALMI® (dexmedetomidine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dexmedetomidine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dexmedetomidine_20261116","title":"IGALMI® (dexmedetomidine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dexmedetomidine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
